We analyzed the efficacy and safety of an everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolic acid with standard-exposure CNI (MPA+sCNI) regimen in Asian patients from the TRANSFORM study. In this 24-month, open-label study, de novo kidney transplant recipients (KTxRs) were randomized (1:1) to receive EVR+rCNI or MPA+sCNI, along with induction therapy and corticosteroids. Of the 2037 patients randomized in the TRANSFORM study, 293 were Asian (EVR+rCNI, N = 136; MPA+sCNI, N = 157). At Month 24, EVR+rCNI was noninferior to MPA+sCNI for the binary endpoint of estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m or treated biopsy-proven acute rejection (27.0% vs 29.2%, P = 0.011 for a noninferiority margin of 10%). Graft loss and death were reported for one patient each in both arms. Mean eGFR was higher in EVR+rCNI versus MPA+sCNI (72.2 vs 66.3 mL/min/1.73 m , P = 0.0414) even after adjusting for donor type and donor age (64.3 vs 59.3 mL/min/1.73 m , P = 0.0582). Overall incidence of adverse events was comparable. BK virus (4.4% vs 12.1%) and cytomegalovirus (4.4% vs 13.4%) infections were significantly lower in the EVR+rCNI arm This subgroup analysis in Asian de novo KTxRs demonstrated that the EVR+rCNI versus MPA+sCNI regimen provides comparable antirejection efficacy, better renal function and reduced viral infections. (NCT01950819) This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.